Vasculitis & polymyalgia rheumatica
Efficacy of Tumor Necrosis Factor Inhibitors for Refractory Leg Ulcers in Cutaneous Polyarteritis Nodosa: A Case Series
Authors' conclusion
TNFi showed therapeutic efficacy for cPAN-associated refractory leg ulcers and enabled ulcer epithelialization and significant GC dose reduction.
Study context
- Population
- Patients with histologically confirmed cutaneous PAN with refractory leg ulcers treated with tumor necrosis factor inhibitor (TNFi), 3 institutions in Japan, 2016–2023; secondary PAN excluded9 female
- Participants
- 10 patients
- Outcome
- Efficacy of TNFi for cutaneous polyarteritis nodosa (cPAN)-associated refractory leg ulcers (ulcer status, GC dosage)
Methodological detailsmulticentre (3 institutions in Japan)
- Multicentre (3 institutions in Japan)
Main finding
As reported in the abstract
Complete epithelialization of leg ulcers
- Complete epithelialization of leg ulcers achieved in all patients
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| GC-free status | TNFi 5 events |
Average glucocorticoid (GC) dose
- Average GC dose reduced from 20 mg/day to 3.5 mg/day
Safety
- No serious adverse events were observed in any of the patients
Original publication
Efficacy of Tumor Necrosis Factor Inhibitors for Refractory Leg Ulcers in Cutaneous Polyarteritis Nodosa: A Case Series. J Rheumatol. Published 15 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →